Metropolitan Life Insurance Company (MetLife)’s Puma Biotechnology PBYI Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-7,892	Closed	-$76.7K	–	2886
2021 Q1	$76.7K	Sell	7,892 -1,563	-17%	-$17.5K	﹤0.01%	2483
2020 Q4	$97K	Hold	9,455	–	–	﹤0.01%	2372
2020 Q3	$95.4K	Sell	9,455 -269	-3%	-$2.74K	﹤0.01%	2245
2020 Q2	$101K	Hold	9,724	–	–	﹤0.01%	2250
2020 Q1	$82.1K	Buy	9,724 +85	+0.9%	+$826	﹤0.01%	2158
2019 Q4	$84.3K	Sell	9,639 -976	-9%	-$8.08K	﹤0.01%	2418
2019 Q3	$114K	Buy	10,615 +1,305	+14%	+$14.1K	﹤0.01%	2227
2019 Q2	$118K	Hold	9,310	–	–	﹤0.01%	2219
2019 Q1	$361K	Sell	9,310 -388	-4%	-$11.8K	0.01%	1506
2018 Q4	$197K	Buy	9,698 +374	+4%	+$11.2K	﹤0.01%	1829
2018 Q3	$428K	Hold	9,324	–	–	0.01%	1483
2018 Q2	$552K	Hold	9,324	–	–	0.01%	1253
2018 Q1	$634K	Buy	9,324 +138	+2%	+$10.3K	0.01%	1124
2017 Q4	$908K	Sell	9,186 -10,440	-53%	-$1.17M	0.01%	944
2017 Q3	$2.35M	Sell	19,626 -159	-0.8%	-$14.8K	0.01%	888
2017 Q2	$1.73M	Sell	19,785 -357	-2%	-$20K	0.01%	993
2017 Q1	$749K	Hold	20,142	–	–	0.01%	1387
2016 Q4	$618K	Buy	20,142 +2,247	+13%	+$97.2K	﹤0.01%	1601
2016 Q3	$1.2M	Sell	17,895 -476	-3%	-$24.1K	0.01%	1188
2016 Q2	$547K	Buy	18,371 +16,496	+880%	+$516K	﹤0.01%	1630
2016 Q1	$55K	Hold	1,875	–	–	﹤0.01%	2460
2015 Q4	$147K	Buy	1,875 +50	+3%	+$3.92K	﹤0.01%	2442
2015 Q3	$138K	Hold	1,825	–	–	﹤0.01%	2515
2015 Q2	$213K	Sell	1,825 -16,950	-90%	-$3.07M	﹤0.01%	2361
2015 Q1	$4.43M	Buy	18,775 +970	+5%	+$207K	0.03%	583
2014 Q4	$3.37M	Hold	17,805	–	–	0.02%	725
2014 Q3	$4.25M	Sell	17,805 -750	-4%	-$154K	0.03%	587
2014 Q2	$1.23M	Hold	18,555	–	–	0.01%	1227
2014 Q1	$1.93M	Buy	18,555 +729	+4%	+$85.7K	0.01%	1002
2013 Q4	$1.85M	Buy	17,826 +1,019	+6%	+$59.8K	0.01%	1016
2013 Q3	$902K	Sell	16,807 -2,456	-13%	-$132K	0.01%	1339
2013 Q2	$855K	Buy	+19,263	New	+$679K	0.01%	1333

Other funds holding PBYI

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s PBYI Position: Q2 2021 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Puma Biotechnology (PBYI) in Q2 2021, closing a stake of 7,892 shares — an estimated $76.7K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in PBYI in Q2 2013 and held it in 32 quarters. The position peaked at $4.43M in Q1 2015. 120 funds tracked by Wall St. Rank hold PBYI as of Q2 2021.

Metropolitan Life Insurance Company (MetLife) reported no remaining Puma Biotechnology position as of Q2 2021 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 7,892 Puma Biotechnology shares in Q2 2021, an estimated $76.7K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Puma Biotechnology in Q2 2013 and held it in 32 quarters.
Metropolitan Life Insurance Company (MetLife)'s Puma Biotechnology position peaked at $4.43M in Q1 2015.
120 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2021.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2021, filed 16 Aug 2021.